{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peng X"],"funding":["Open Funds of State Key Laboratory of Oncology in South China","Fellowship of China Postdoctoral Science Foundation","National Natural Science Foundation of China","ISF and NSFC Israel-China project"],"pagination":["54"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10938783"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["Background
Phosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse cellular functions and have emerged as promising targets in cancer therapy. Despite significant progress, existing PI3K inhibitors encounter various challenges such as suboptimal bioavailability, potential off-target effects, restricted therapeutic indices, and cancer-acquired resistance. Hence, novel inhibitors that overcome some of these challenges are needed. Here, we describe the characterization of KTC1101, a novel pan-PI3K inhibitor that simultaneously targets tumor cell proliferation and the tumor microenvironment. Our studies demonstrate that KTC1101 significantly increases the anti-PD-1 efficacy in multiple pre-clinical mouse models.Methods
KTC1101 was synthesized and characterized emp"],"journal":["Molecular cancer"],"pubmed_title":["A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation."],"pmcid":["PMC10938783"],"funding_grant_id":["#3409/20","2021M702464","82204460","82204461","82061148017","HN2023-05"],"pubmed_authors":["Peng X","Cohen L","Wang F","Elkabets M","Kong D","Liu S","Zhang S","Wang K","Dan S","Huang S","Lulu TB","Fan J","Zhang Z","Isoyama S","Huang X","Jia W","Chen X","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.","description":"Background
Phosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse cellular functions and have emerged as promising targets in cancer therapy. Despite significant progress, existing PI3K inhibitors encounter various challenges such as suboptimal bioavailability, potential off-target effects, restricted therapeutic indices, and cancer-acquired resistance. Hence, novel inhibitors that overcome some of these challenges are needed. Here, we describe the characterization of KTC1101, a novel pan-PI3K inhibitor that simultaneously targets tumor cell proliferation and the tumor microenvironment. Our studies demonstrate that KTC1101 significantly increases the anti-PD-1 efficacy in multiple pre-clinical mouse models.Methods
KTC1101 was synthesized and characterized emp","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-01T11:50:16.95Z","creation":"2024-11-20T19:06:12.816Z"},"accession":"S-EPMC10938783","cross_references":{"pubmed":["38486218"],"doi":["10.1186/s12943-024-01978-0"]}}